TSHA Stock Forecast & Price Target

Taysha Gene Therapies is diligently advancing its pipeline with updates on enrollment progress for both its Part B pivotal trial, featuring a responder analysis, and an interim analysis on its single-arm, open-label Part A data with substantial long-term safety and efficacy in Q2/26, followed by ASPIRE safety trial enrollment in 2-4 year olds, potentially leading to a potential filing of a biologics license application, highlighting in confidence their current release with respect the FDA's January 2026 alignment. Given these recent developments, the once high AAV-based gene therapies platform risk seems to have been, for Taylor Gene Therapies, lifted materially and is no cause for immediate pricing concern for the biotech, as credibility for the unheard Rett Syndrome rare neurodevelopmental disorder and the company's proprietary TSHA-102 suggest.

Taysha Gene Therapies is a newly established biotechnology company with a limited pipeline and relatively high operating costs. Despite having one of the most promising treatments for Rett syndrome, the company faces significant competition from other gene therapy companies. Additionally, the uncertainty surrounding the regulatory approval process for gene therapies and the need for significant capital to fund operations and commercialization efforts make the stock a risky investment.